Protein X-ray Crystallography and Drug Discovery

Abstract

With the advent of structural biology in the drug discovery process, medicinal chemists gained the opportunity to use detailed structural information in order to progress screening hits into leads or drug candidates. X-ray crystallography has proven to be an invaluable tool in this respect, as it is able to provide exquisitely comprehensive structural information about the interaction of a ligand with a pharmacological target. As fragment-based drug discovery emerged in the recent years, X-ray crystallography has also become a powerful screening technology, able to provide structural information on complexes involving low-molecular weight compounds, despite weak binding affinities. Given the low numbers of compounds needed in a fragment library, compared to the hundreds of thousand usually present in drug-like compound libraries, it now becomes feasible to screen a whole fragment library using X-ray crystallography, providing a wealth of structural details that will fuel the fragment to drug process. Here, we review theoretical and practical aspects as well as the pros and cons of using X-ray crystallography in the drug discovery process.

Acute Intermittent Porphyria: An Overview of Therapy Developments and Future Perspectives Focusing on Stabilisation of HMBS and Proteostasis Regulators

“…Regarding proteins, it can give detailed information on protein structure, function, and interactions, e.g., the molecular changes during substrate binding and enzymatic catalysis, how drug molecules interact with their target, and how modifications could alter the interactions or the mechanism. In general, structural studies of disease-related proteins play an important role in drug discovery, not only by providing fundamental information about protein function or specific drug binding, but also by presenting more information for hit-to-lead optimisation or for the development of chemoinformatics and medicinal chemistry programs [ 205 , 206 ]. In the search for, e.g., pharmacological chaperones, well-defined crystal structures are particularly important in docking-based in silico screenings to identify and characterize binders.…”

Targeting protein–protein interactions in the DNA damage response pathways for cancer chemotherapy

“…61,62 Structure determination of protein -small molecule complexes by X-ray crystallography is an integral step in the SBDD hit validation commonly used to verify ligand binding to the target interface and identify critical SAR for hit compounds. 87,88 Crystallization of a ligand-protein complex is usually performed by crystal soaking whereby an inhibitor is incubated with protein crystals, or co-crystallization whereby an inhibitor is mixed with protein solution prior to crystallization. Each of these methods has advantages and limitations.…”

Chimeric Claudins: A New Tool to Study Tight Junction Structure and Function

“…Unfortunately, these peptides remain as research tools only. Understanding CLDN structure and TJ assembly will be key steps for drug discovery [ 48 ] and translational solutions.…”